A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Angie explores with her guest authors the practice of micro-dosing – which, they say, does NOT mean tripping on psychedelics.

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

By Karen Roman Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction. Additionally, ...

The trial is jointly conducted at the Fudan University Shanghai Cancer Center and Peking University Cancer Hospital.

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...